SCHEMBL3901196

SCHEMBL3901196

CC(=O)Nc1ncc(-c2cncc(N)c2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.45
LIMK1 P53667 4/20 0.44
PIK3CA P42336 3/20 0.43
CYP3A4 P08684 2/20 0.43
KDR P35968 1/20 0.43
PIK3CG P48736 5/20 0.42
LIMK2 P53671 3/20 0.41
TESK2 Q96S53 2/20 0.41
TESK1 Q15569 1/20 0.41
CLK1 P49759 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3R1 P27986 1/20 0.41
GSTO1 P78417 1/20 0.40
CCNE1 P24864 2/20 0.39
CDK2 P24941 2/20 0.39
CDK5 Q00535 1/20 0.39
SCD O00767 1/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CHEK1 O14757 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12991170 0.80 MEN1 (0.48) LIMK1PIK3CACYP3A4KDRPIK3CG
SCHEMBL3904608 0.78 LIMK1 (0.45) LIMK1PIK3CACYP3A4KDRPIK3CG
SCHEMBL3905457 0.77 LIMK1 (0.46) LIMK1PIK3CACYP3A4PIK3CGLIMK2
SCHEMBL925427 0.76 PIK3CG (0.56) ATAD2PIK3CAPIK3CGPIK3CDPIK3R1
SCHEMBL5840422 0.75 KDR (0.72) LIMK1KDRGSTO1CCNE1CDK2
SCHEMBL25682571 0.75 KDR (0.44) CYP3A4KDRGSTO1CCNE1CDK2
SCHEMBL17632040 0.72 ABL1 (0.62) LIMK1KDRPIK3CGGSTO1CCNE1
SCHEMBL13158536 0.72 CCNE1 (0.48) PIK3CACYP3A4CLK1CCNE1CDK2
SCHEMBL25683131 0.71 POLB (0.51) LIMK1KDRGSTO1CCNE1CDK2
SCHEMBL9285608 0.71 ALDH1A1 (0.51) LIMK1PIK3CAKDRPIK3CGPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101484452-A Thiazole derivatives and their use as anti-tumour agents ASTRAZENECA AB (SE) 2009-07-15 CN disclosed
US-20090076009-A1 THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS ASTRAZENECA AB (SE) 2009-03-19 US disclosed
EP-2016075-A1 THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS AstraZeneca AB (SE) 2009-01-21 EP disclosed
WO-2007129044-A1 THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS ASTRAZENECA AB (SE) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076009-A1 THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS MTOR, RPTOR, JAK2 ATAD2 2025/4885LIMK1 709/4885PIK3CA 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.